BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published:October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Longer caregiving hours tied to worse menopause symptoms in women January 30, 2025 Vitamin D supplements during pregnancy strengthen children’s bones November 6, 2024 Breath analysis promises rapid diagnosis of lower respiratory infections September 24, 2024